Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Income from Non-Controlling Interests: 2023-2025

Historic Income from Non-Controlling Interests for Gyre Therapeutics (GYRE) over the last 3 years, with Sep 2025 value amounting to $2.3 million.

  • Gyre Therapeutics' Income from Non-Controlling Interests rose 34.30% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 0.19%. This contributed to the annual value of $5.8 million for FY2024, which is 22.00% down from last year.
  • As of Q3 2025, Gyre Therapeutics' Income from Non-Controlling Interests stood at $2.3 million, which was up 105.11% from $1.1 million recorded in Q2 2025.
  • Gyre Therapeutics' Income from Non-Controlling Interests' 5-year high stood at $3.5 million during Q3 2023, with a 5-year trough of $29,000 in Q4 2023.
  • Its 3-year average for Income from Non-Controlling Interests is $1.6 million, with a median of $1.7 million in 2024.
  • Its Income from Non-Controlling Interests has fluctuated over the past 5 years, first surged by 2,203.45% in 2024, then crashed by 56.89% in 2025.
  • Gyre Therapeutics' Income from Non-Controlling Interests (Quarterly) stood at $29,000 in 2023, then soared by 2,203.45% to $668,000 in 2024, then surged by 34.30% to $2.3 million in 2025.
  • Its Income from Non-Controlling Interests was $2.3 million in Q3 2025, compared to $1.1 million in Q2 2025 and $1.0 million in Q1 2025.